Public-registry trials using OT202 conc 1% that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Phase III Study of OT202 in Treating Moderate to Severe Dry Eye | Ocumension Therapeutics (Suzhou) Co., Ltd | Dry Eye | PHASE3 | 49 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →